Same-arm influenza and COVID vaccination did not weaken antibody responses
A randomized trial in adults found no meaningful immunogenic penalty when an inactivated influenza vaccine and a SARS-CoV-2 mRNA vaccine were given in the same arm rather than in opposite arms. The result matters because many clinicians and patients still face a practical question at the point of vaccination: whether separating injection sites improves immune responses enough to justify the extra logistics. In this study, the answer for influenza was no. The combined serum hemagglutination inhibition response to the H1, H3, and B-Vic strains was not significantly different between groups, even though the same-arm cohort showed a numerically higher titer.
The trial compared Afluria quadrivalent with the Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccine in 56 adults. Participants were randomly assigned to receive the two vaccines either in opposite arms or in the same arm at the same site. The primary endpoint focused on the difference in median combined serum hemagglutination inhibition titer after vaccination, a standard laboratory readout that tracks the functional ability of antibodies to block viral attachment to red blood cells. That assay remains a useful proxy for influenza vaccine response because it captures strain-specific antibody activity rather than only the presence of binding antibodies.
No significant difference emerged in the primary analysis. The P value was 0.30, and the same-arm group had a 1.26-fold higher titer than the opposite-arm group. On paper, that directional shift sounds interesting; in practice, it did not cross the threshold for statistical significance and did not support a claim that same-arm administration improves influenza protection. The absence of a robust effect also fits basic vaccine immunology. If two injected products were to interfere materially with each other, one would expect a clearer drop in the shared immune readout, not a small numerical fluctuation that could easily reflect chance in a modestly sized trial.
No signal of clinically meaningful interference with influenza immunity
The influenza data did not stop at the combined titer. Analyses of antibodies against individual influenza strains also failed to show differences between the same-arm and opposite-arm groups. Nasal and saliva antibody levels were similarly unchanged. Those mucosal findings are important because respiratory viruses enter through the airway, and a theoretical concern around vaccine placement is that local immune priming might vary depending on whether two vaccines drain to the same regional lymphatic basin. The trial did not support that concern in any measurable way.
That said, the study was not designed to prove superiority of either strategy. It was built to ask a narrower question: whether coadministration in one arm compromises the influenza response compared with distributing the injections across both arms. On that point, the data are reassuring. Current practice can therefore remain flexible for influenza vaccination when a SARS-CoV-2 vaccine is given at the same visit, and the needle-site choice does not appear to carry an obvious immunologic cost for the influenza component.
SARS-CoV-2 responses pointed in a different direction
The SARS-CoV-2 antibody results were more complicated. Binding and neutralizing antibody titers after vaccination were not significantly different between groups overall, yet the opposite-arm group had a higher fold-change in neutralizing antibodies against BA.5 and the ancestral strain. Those strain-specific differences do not overturn the main conclusion, but they do keep the biology interesting. mRNA vaccines can behave like potent adjuvant systems, and the local immune environment created by one vaccine may influence the kinetics of response to another when they are placed in close proximity. The murine literature has suggested such effects are plausible, especially when vaccines are coformulated or codelivered. Human data here did not show a broad influenza advantage from same-arm delivery, but the SARS-CoV-2 signal suggests injection-site geography may still shape parts of the immune response in subtle ways.
This is where bedside interpretation needs restraint. A higher fold-change in selected neutralizing antibody measurements does not automatically translate into better protection, and the trial did not report clinical infection outcomes. Laboratory immunogenicity is informative, but it is still a surrogate. In a small randomized cohort, strain-specific changes can reflect real biology, random variation, or both. The finding is enough to discourage overstatement, not enough to change vaccination policy on its own.
What the trial supports in routine vaccination practice
For everyday vaccination visits, the clearest message is operational rather than dramatic. Influenza vaccination remains equivalently immunogenic whether given in the same arm or the opposite arm as the SARS-CoV-2 vaccine. That leaves room for practical decisions based on patient comfort, prior local reactions, or clinic workflow. If a patient wants both shots placed in one arm to simplify administration, this trial does not suggest influenza immunity will suffer. If separate arms are preferred to reduce local soreness or to make side effects easier to attribute, that approach also remains reasonable.
The trial registration and funding details reinforce its place as a formal randomized study rather than an informal observation. It was registered under ACTRN12624000445572 and supported by the Australian National Health and Medical Research Council, the Australian Medical Research Future Fund, and the National Institutes of Health through UH2AI176172. The sample size was small, however, and that should be kept front and center when translating the findings. A 56-person study can identify clear immunologic separation if one exists, but it can also miss smaller effects and cannot answer questions about clinical effectiveness, durability of protection, or rare adverse events.
Small sample, narrow question, useful answer
This trial answered a very specific practical question with appropriate rigor. It did not show a reason to move influenza and COVID vaccines into different arms for the sake of influenza immunogenicity, and it did not reveal a large, consistent disadvantage to same-arm administration. The residual uncertainty sits in the SARS-CoV-2 strain-specific fold-change findings and in the lack of clinical outcome data. Larger studies will be needed before anyone can say whether injection-site selection alters protection in a way that matters beyond the laboratory.